2. Search Result
Search Result
Results for "

esophageal

" in MedChemExpress (MCE) Product Catalog:

41

Inhibitors & Agonists

5

Peptides

1

MCE Kits

3

Inhibitory Antibodies

4

Natural
Products

2

Click Chemistry

Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-147298
    Plogosertib

    CYC140

    		 Polo-like Kinase (PLK) Cancer
    Plogosertib (CYC140) is a selective, potent, and orally active ATP-competitive PLK1 inhibitor (IC50: 3 nM). Plogosertib is an anti-cancer agent with anti-proliferative activity. Plogosertib can be used in the research of several tumors, including esophageal, gastric, leukemia, non–small cell lung cancer, ovarian, and squamous cell cancers .
    Plogosertib
  • HY-12204
    PFK-015
    3 Publications Verification

    		 Autophagy Metabolic Disease Inflammation/Immunology Cancer
    PFK-015, a derivative of 3PO, is a specific PFKFB3 inhibitor. PFK-015 inhibits recombinant PFKFB3 with an IC50 value of 110 nM and inhibits PFKFB3 activity in cancer cells with an IC50 value of 20 nM. PFK-015 can be used for the research of multiple cancers such as lung cancer, stomach cancer, colon cancer and esophageal squamous cell carcinoma (ESCC) .
    PFK-015
  • HY-P99846
    Dectrekumab

    QAX576

    		 Interleukin Related Inflammation/Immunology
    Dectrekumab (QAX576) is a human monoclonal antibody that targets IL-13. Dectrekumab significantly improves intraepithelial esophageal eosinophil counts and dysregulated esophageal disease-related transcripts with Eosinophilic esophagitis (EoE) in a sustained manner and can be used for inflammation and immunology related research .
    Dectrekumab
  • HY-157030
    NIEA

    		Others Cancer
    NIEA is a potent carcinogen that induce pancreatic cancer, esophageal cancer and hepatocellular carcinoma .
    NIEA
  • HY-119906
    Conglobatin

    FW-04-806

    		 HSP Apoptosis Cancer
    Conglobatin (FW-04-806), a macrolide dilactone, is isolated from the culture of Streptomyces conglobatus. Conglobatin is an orally active Hsp90 inhibitor. Conglobatin can bind to the N-terminal domain of Hsp90 and disrupt Hsp90-Cdc37 complex formation. Conglobatin induces apoptosis in human breast cancer cells and esophageal squamous cell carcinoma cells, and exhibits antitumor activity in vivo .
    Conglobatin
  • HY-B2106
    Polidocanol

    Polyoxyethylene lauryl ether; Polyoxyethyleneglycol Dodecyl Ether

    		 Others Cardiovascular Disease
    Polidocanol is a sclerosing agent used successfully to treat extremity and esophageal varices and telangiectasias.
    Polidocanol
  • HY-W195048
    Tetradecyl sulfate sodium

    		Others Cardiovascular Disease
    Tetradecyl sulfate sodium, a detergent sclerosant, is widely used to research for esophageal varices and varicose veins .
    Tetradecyl sulfate sodium
  • HY-B0432
    Propafenone

    SA-79

    		 Sodium Channel Adrenergic Receptor Potassium Channel Cardiovascular Disease Cancer
    Propafenone (SA-79), a sodium-channel blocker, acts an antiarrhythmic agent. Propafenone also has high affinity for the β receptor (IC50=32 nM) . Propafenone blocks the transient outward current (Ito) and the sustained delayed rectifier K current (Isus) with IC50 values of 4.9 μm and 8.6 μm, respectively . Propafenone suppresses esophageal cancer proliferation through inducing mitochondrial dysfunction and induce apoptosis .
    Propafenone
  • HY-106258
    Atilmotin

    OHM 11638; BAX-ACC 1638; MOT 288

    		 Motilin Receptor Metabolic Disease
    OHM 11638 (Atilmotin), an analogue of the (1-14) fragment of porcine motilin, is a motilin receptor agonist with a pKd of 8.94 for the motilin receptor. OHM 11638 affects esophageal, lower esophageal sphincter (LES), and gastric motility. OHM 11638 increases LES and gastric pressures, OHM 11638 can be used as prokinetic agents .
    Atilmotin
  • HY-N1476
    Heterophyllin B
    2 Publications Verification
    Heterophyllin B is an active cyclic peptide isolated from Pseudostellaria heterophylla. Heterophyllin B provides a novel strategy for the treatment of esophageal cancer .
    Heterophyllin B
  • HY-N11050
    Xerophilusin B

    		Apoptosis Cancer
    Xerophilusin B, an anticancer agent isolated from Isodon xerophilus, exhibits antiproliferative effects on esophageal squamous cell carcinoma (ESCC) cell lines, induces G2/M cell cycle arrest, and mediates apoptosis .
    Xerophilusin B
  • HY-33354
    Nitrochin

    4-NQO
    Nitrochin (4-NQO) is a chemical carcinogen. Nitrochin induces oncostatin-M (OSM) in esophageal cells. Nitrochin induces DNA damage, and induces apoptosis via a p53-dependent mitochondrial signaling pathway .
    Nitrochin
  • HY-151934
    ERK-IN-6

    		Apoptosis Cancer
    ERK-IN-6 (compound 6g) is an potent anti-proliferation agent against esophageal squamous cell carcinoma (ESCC). ERK-IN-6 induces cell apoptosis via ERK pathway. ERK-IN-6 can be used for the research of ESCC .
    ERK-IN-6
  • HY-114338
    Dalpiciclib

    SHR-6390

    		 CDK Cancer
    Dalpiciclib (SHR-6390) is an orally active and highly selective inhibitor of CDK4 and 6 with IC50 values of 12.4 nM and 9.9 nM, respectively . Dalpiciclib shows antitumor activity against breast cancer and esophageal squamous cell carcinoma .
    Dalpiciclib
  • HY-108527
    CD1530

    		RAR/RXR Cancer
    CD1530 is a selective RARγ agonist with an Kd of 150 nM . CD1530 has been used in combination with bexarotene to inhibit oral carcinogenesis induced by the carcinogen 4-nitroquinoline 1-oxide in a mouse model of human oral-cavity and esophageal squamous-cell carcinoma .
    CD1530
  • HY-114338A
    Dalpiciclib hydrochloride

    SHR-6390 hydrochloride

    		 CDK Cancer
    Dalpiciclib (SHR-6390) hydrochloride is an orally active and highly selective inhibitor of CDK4 and 6 with IC50 values of 12.4 nM and 9.9 nM, respectively . Dalpiciclib hydrochloride shows antitumor activity against breast cancer and esophageal squamous cell carcinoma .
    Dalpiciclib hydrochloride
  • HY-126324
    IV-23

    		Apoptosis Cancer
    IV-23 (Compound 20) is a potent Noxa mediated apoptosis inducer, and it is a promising anticancer agent with potential. IV-23 inhibits cell growths in vitro and in vivo, reduces colony formation, arrests cell cycle at M phase, and induces esophageal squamous cell carcinoma (ESCC) .
    IV-23
  • HY-N9507
    Picrasidine Q

    		Apoptosis FGFR Cancer
    Picrasidine Q, an alkaloid component extracted from Angelica keiskei species, has the capacity of anti-cell transformation and anti-cancer. Picrasidine Q induces cell apoptosis and G1 phase arrest in human esophageal cancer cell lines, and directly inhibits FGFR2 kinase activity .
    Picrasidine Q
  • HY-100413
    CS-526

    CS-526 is a potent, selective, reversible and orally active acid pump antagonist. CS-526 inhibits H +,K +-ATPase activity. CS-526 inhibits gastric acid secretion and prevents esophageal lesions. CS-526 has the potential for the research of gastroesophageal reflux disease .
    CS-526
  • HY-B0732
    Itopride hydrochloride

    HSR803

    		 Cholinesterase (ChE) Dopamine Receptor Bacterial Neurological Disease
    Itopride (HSR803) hydrochloride is a potent dopamine-2 antagonist and an acetylcholine esterase (AChE) inhibitor. Itopride hydrochloride enhances gastric motility through both antidopaminergic and anti-acetylcholinesterasic actions, can be used as a gastrointestinal prokinetic agent. Itopride can be used for researching gastro-esophageal reflux disease (GERD) .
    Itopride hydrochloride
  • HY-B0732A
    Itopride

    HSR803 free base

    		 Cholinesterase (ChE) Dopamine Receptor Bacterial Others
    Itopride (HSR803 free base) is a potent and orally active dopamine-2 antagonist and an acetylcholine esterase (AChE) inhibitor. Itopride enhances gastric motility through both antidopaminergic and anti-acetylcholinesterasic actions, can be used as a gastrointestinal prokinetic agent. Itopride can be used for researching gastro-esophageal reflux disease (GERD) .
    Itopride
  • HY-131649
    Compound C108

    		Others Cancer
    Compound C108 is a G3BP2 inhibitor. Compound C108 also targeted stress granule-associated proteins and Gtpase-activating protein (SH3 domain) binding protein 2. Compound C108 potently inhibits esophageal squamous cell carcinoma (ESCC) cell metastasis .
    Compound C108
  • HY-P99594
    Socazolimab

    ZKAB001; STI-1014; STI-A1014

    		 PD-1/PD-L1 Cancer
    Socazolimab (ZKAB001) is an anti-PD-L1 monoclonal antibody. Socazolimab has lasting safety and efficacy in the treatment of recurrent or metastatic cervical cancer. Socazolimab also has potential applications in small cell lung cancer, esophageal squamous cell carcinoma (ESCC), advanced urothelial carcinoma and osteosarcoma .
    Socazolimab
  • HY-P0004
    Lysipressin
    2 Publications Verification

    Lysine vasopressin; [Lys8]-Vasopressin

    		 Adenylate Cyclase Others
    Lysipressin (Lysine vasopressin) is antidiuretic hormone that have been found in pigs and some marsupial families. Lysipressin induces contraction of the rabbit urinary bladder smooth muscle, activate adenylate-cyclase .
    Lysipressin
  • HY-P0004A
    Lysipressin acetate
    2 Publications Verification

    Lysine vasopressin acetate; [Lys8]-Vasopressin acetate

    		 Adenylate Cyclase Others
    Lysipressin (Lysine vasopressin) acetate is antidiuretic hormone that have been found in pigs and some marsupial families. Lysipressin acetate induces contraction of the rabbit urinary bladder smooth muscle, activate adenylate-cyclase .
    Lysipressin acetate
  • HY-10061
    Lesogaberan

    AZD-3355

    		 GABA Receptor Metabolic Disease
    Lesogaberan (AZD-3355) is a potent and selective GABAB receptor agonist with an EC50 of 8.6 nM for human recombinant GABAB receptors. The affinity (Kis) of Lesogaberan for rat GABAB and GABAA receptors, as measured by displacement of [ 3H]GABA binding in brain membranes: 5.1 nM and 1.4 μM, respectively. Lesogaberan inhibits transient lower esophageal sphincter relaxation through a peripheral mode of action .
    Lesogaberan
  • HY-B1367
    Carbenoxolone disodium
    1 Publications Verification
    Carbenoxolone disodium is the active metabolite of Glycyrrhizic acid (HY-N0184) and the inhibitor of human 11β-HSD and bacterial 3α, 20β-HSD . Carbenoxolone disodium is an uncoupling agent for gap junctions and a potent inhibitor of Vaccinia virus replication . Carbenoxolone disodium is used for the study of peptic, esophageal and oral ulceration and inflammation. Carbenoxolone disodium inhibits Vaccinia virus replication.
    Carbenoxolone disodium
  • HY-10061B
    Lesogaberan hydrochloride

    AZD-3355 hydrochloride

    		 GABA Receptor Metabolic Disease
    Lesogaberan (AZD-3355) hydrochloride is a potent and selective GABAB receptor agonist with an EC50 of 8.6 nM for human recombinant GABAB receptor. The affinity (Kis) of Lesogaberan hydrochloride for rat GABAB and GABAA receptors, as measured by displacement of [ 3H]GABA binding in brain membranes: 5.1 nM and 1.4 μM, respectively. Lesogaberan hydrochloride inhibits transient lower esophageal sphincter relaxation through a peripheral mode of action .
    Lesogaberan hydrochloride
  • HY-10061A
    Lesogaberan napadisylate

    AZD-3355 napadisylate

    		 GABA Receptor Metabolic Disease
    Lesogaberan (AZD-3355) napadisylate is a potent and selective GABAB receptor agonist with an EC50 of 8.6 nM for human recombinant GABAB receptors. The affinity (Kis) of Lesogaberan napadisylate for rat GABAB and GABAA receptors, as measured by displacement of [ 3H]GABA binding in brain membranes: 5.1 nM and 1.4 μM, respectively. Lesogaberan napadisylate inhibits transient lower esophageal sphincter relaxation through a peripheral mode of action .
    Lesogaberan napadisylate
  • HY-104066
    Theliatinib

    Xiliertinib; HMPL-309

    		 EGFR Cancer
    Theliatinib (Xiliertinib) is a potent, ATP-competitive, orally active and highly selective EGFR inhibitor with a Ki of 0.05 nM and an IC50 of 3 nM. Theliatinib has an IC50 of 22 nM for EGFR T790M/L858R mutant. Theliatinib shows >50-fold selectivity for EGFR than other kinases . Theliatinib is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.
    Theliatinib
  • HY-147874
    ANO1-IN-3

    		Chloride Channel Apoptosis Cancer
    ANO1-IN-3 (Compound 3n) is a potent and selective ANO1 inhibitor with an IC50 of 1.23 μM. ANO1-IN-3 induces apoptosis .
    ANO1-IN-3
  • HY-104066A
    Theliatinib tartrate

    Xiliertinib tartrate; HMPL-309 tartrate

    		 EGFR Cancer
    Theliatinib (Xiliertinib) tartrate is a potent, ATP-competitive, orally active and highly selective EGFR inhibitor with a Ki of 0.05 nM and an IC50 of 3 nM. Theliatinib has an IC50 of 22 nM for EGFR T790M/L858R mutant. Theliatinib shows >50-fold selectivity for EGFR than other kinases . Theliatinib (tartrate) is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.
    Theliatinib tartrate
  • HY-10261
    Afatinib
    Maximum Cited Publications
    53 Publications Verification

    BIBW 2992

    		 EGFR Autophagy Apoptosis c-Met/HGFR Akt p38 MAPK Cancer
    Afatinib (BIBW 2992) is an orally active, potent and irreversible dual specificity inhibitor of ErbB family (EGFR and HER2), with IC50 values of 0.5 nM, 0.4 nM, 10 nM and 14 nM for EGFR wt, EGFR L858R, EGFR L858R/T790M and HER2, respectively. Afatinib can be used for the research of esophageal squamous cell carcinoma (ESCC), non-small cell lung cancer (NSCLC) and gastric cancer .
    Afatinib
  • HY-10261A
    Afatinib dimaleate
    Maximum Cited Publications
    53 Publications Verification

    BIBW 2992MA2

    		 EGFR Autophagy Apoptosis c-Met/HGFR Akt p38 MAPK Cancer
    Afatinib (BIBW 2992) dimaleate is an orally active, potent and irreversible dual specificity inhibitor of ErbB family (EGFR and HER2), with IC50 values of 0.5 nM, 0.4 nM, 10 nM and 14 nM for EGFR wt, EGFR L858R, EGFR L858R/T790M and HER2, respectively. Afatinib dimaleate can be used for the research of esophageal squamous cell carcinoma (ESCC), non-small cell lung cancer (NSCLC) and gastric cancer .
    Afatinib dimaleate
  • HY-10261D
    Afatinib oxalate

    BIBW 2992 oxalate

    		 EGFR Autophagy Apoptosis c-Met/HGFR Akt Cancer
    Afatinib (BIBW 2992) oxalate is an orally active, potent and irreversible dual specificity inhibitor of ErbB family (EGFR and HER2), with IC50 values of 0.5 nM, 0.4 nM, 10 nM and 14 nM for EGFR wt, EGFR L858R, EGFR L858R/T790M and HER2, respectively. Afatinib oxalate can be used for the research of esophageal squamous cell carcinoma (ESCC), non-small cell lung cancer (NSCLC) and gastric cancer .
    Afatinib oxalate
  • HY-10261E
    (R)-Afatinib

    (R)-BIBW 2992

    		 EGFR c-Met/HGFR p38 MAPK Cancer
    (R)-Afatinib ((R)-BIBW 2992) is the Afatinib isomer. Afatinib (HY-10261) is an orally active, potent and irreversible dual specificity inhibitor of ErbB family (EGFR and HER2), with IC50 values of 0.5 nM, 0.4 nM, 10 nM and 14 nM for EGFR wt, EGFR L858R, EGFR L858R/T790M and HER2, respectively. Afatinib can be used for the research of esophageal squamous cell carcinoma (ESCC), non-small cell lung cancer (NSCLC) and gastric cancer .
    (R)-Afatinib
  • HY-105930
    Lobaplatin
    2 Publications Verification

    D-19466

    		 Apoptosis Caspase Bcl-2 Family Cancer
    Lobaplatin (D-19466) is a diastereometric mixture of platinum(II) complexe. Lobaplatin arrests cell cycle at G1 and G2/M phase. Lobaplatin induces apoptosis by increasing expressions of caspase and Bax, decreasing expression of Bcl-2. Lobaplatin can be used for research of cancer .
    Lobaplatin
  • HY-139612
    Opnurasib
    1 Publications Verification

    JDQ-443; NVP-JDQ443

    		 Ras PERK Cancer
    Opnurasib (JDQ-443) (NVP-JDQ443) is an orally active, potent, selective, and covalent KRAS G12C inhibitor (extracted from patent WO2021120890A1). Opnurasib shows antitumor activity .
    Opnurasib
  • HY-121607
    INI-43

    		AP-1 Apoptosis Cancer
    INI-43 is an inhibitor of Kpnβ1, interfering with the nuclear localization of Kpnβ1 and known Kpnβ1 cargo proteins, NFAT, NFκB, AP-1, and NFY. INI-43 can inhibit the proliferation of cancer cells, cause G2-M cell cycle arrest in cancer cells, and induce the intrinsic apoptosis pathway .
    INI-43
  • HY-139612A
    (S)-JDQ-443

    (S)-NVP-JDQ443

    		 Ras PERK Cancer
    (S)-JDQ-443 is an isomer of JDQ-443 (HY-139612). JDQ-443 is an orally active, potent, selective, and covalent KRAS G12C inhibitor (extracted from patent WO2021120890A1). JDQ-443 shows antitumor activity .
    (S)-JDQ-443
  • HY-P9971
    Camrelizumab
    1 Publications Verification

    SHR-1210

    		 PD-1/PD-L1 Cancer
    Camrelizumab (SHR-1210) is a potent humanied high-affinity IgG4-κ monoclonal antibody (mAb) to PD-1. Camrelizumab binds PD-1 at a high affinity of 3 nM and inhibits the binding interaction of PD-1 and PD-L1 with an IC50 of 0.70 nM. Camrelizumab acts as anti-PD-1/PD-L1 agent and can be used for cancer research, including NSCLC, ESCC, Hodgkin lymphoma, and advanced HCC et,al .
    Camrelizumab

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: